[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropathyperipheral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropathyperipheral":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,78,103,127,149,171,194,221,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622748","feasibility-and-clinical-utility-of-paired-non-invasive-hemodynamic-and-tissue-oximetry-monitoring-to-detect-limb-ischemia-in-lithotomy-positioned-surgeries-100622748",false,"NCT07387653","Feasibility and Clinical Utility of Paired Non-Invasive Hemodynamic and Tissue Oximetry Monitoring to Detect Limb Ischemia in Lithotomy-Positioned Surgeries","LIMB","Inclusion Criteria:\n\n1. Adult patients\n2. Undergoing minimally invasive pelvic surgery (such as hysterectomy, myomectomy, or endometriosis surgery)\n3. Surgery performed in lithotomy position\n4. Expected surgical duration \\> 2 hours as determined by the primary surgeon\n\nExclusion Criteria:\n\n1. Pregnant patients\n2. Procedures expected to last \\\u003C 2 hours\n3. Open surgical approaches\n4. Minor procedures\n5. Known allergy or sensitivity to adhesives used for monitoring sensors\n6. Vulnerable populations (incarcerated, elderly or pregnant)",true,"FEMALE",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","The LIMB Study is a prospective, observational pilot study evaluating the feasibility of combined non-invasive hemodynamic and lower-limb tissue oximetry monitoring during prolonged minimally invasive pelvic surgeries performed in lithotomy position. Thirty patients will undergo continuous intraoperative monitoring, with the primary outcome being the frequency and duration of tissue oxygen desaturation events and secondary outcomes examining correlations with postoperative limb pain, sensation, and motor function. The study is non-interventional, poses minimal risk, and aims to generate preliminary data to inform future strategies for early detection and prevention of limb ischemia and well-leg compartment syndrome",[24,25],"Neuropathy;Peripheral","Limb Ischemia",[27,28,29,30],"trendelemberg","nerve injury","position nerve injury","prolonged surgery","RECRUITING","2026-05-12",{"date":34,"type":35},"2026-05-14","ACTUAL",{"date":37,"type":35},"2026-01-29",{"date":39,"type":20},"2026-12",{"name":41,"class":42},"The University of Texas Health Science Center, Houston","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100625815","exploration-of-circulating-micrornas-as-biomarkers-of-chemo-induced-peripheral-neuropathy-a-study-in-cancer-patients-100625815","NCT07427537","Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients","miR-CIPN#1","Inclusion Criteria:\n\n* Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or\n* Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.\n\nExclusion Criteria:\n\n* Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),\n* History of stroke,\n* Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15\u002F100),\n* Pain (NRS ≥ 4\u002F10),\n* Pregnant or breastfeeding women,\n* Patients under guardianship, curatorship, deprived of liberty, or under legal protection","ALL","18 Years",{"count":54,"type":20},90,"INTERVENTIONAL",[57],"NA","This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).",[60,61,24],"Cancer, Lung","Colon Neoplasm",[63,64,65,66,67,68],"biomarker","colorectal cancer","lung cancer","oxaliplatin","paclitaxel","chemotherapy-induced peripheral neuropathy","2026-02-16",{"date":71,"type":35},"2026-02-23",{"date":37,"type":35},{"date":74,"type":20},"2028-07-31",{"name":76,"class":42},"University Hospital, Clermont-Ferrand",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":77},"100288664","depolarising-electrical-skin-stimulation-in-neuropathic-and-postoperative-pain-100288664","NCT03037684","Depolarising Electrical Skin Stimulation in Neuropathic and Postoperative Pain","Selective Activation of Unmyelinated Skin Nerve Fibres Using Slow Depolarising Transcutaneous Electrical Stimulation in Patients With Neuropathic Pain or Chronic Postoperative Pain","Inclusion Criteria:\n\n* Group (1) patients with neuropathic pain\n* Group (2) patients with chronic postoperative pain\n\nExclusion Criteria (both Groups):\n\n* severe psychiatric disorder requiring hospitalisation in the past\n* any neurological disease other than the pain diagnosis","65 Years",{"count":87,"type":20},75,"The aim of the study is to evaluate voltage gated sodium channel (NaV1.7) dependent pain phenomena in neuropathic pain and chronic postoperative pain.",[24],[91,92],"neuropathic pain","chronic postoperative pain","2025-12-01",{"date":95,"type":35},"2025-12-08",{"date":97,"type":35},"2017-03-27",{"date":99,"type":20},"2025-12-31",{"name":101,"class":102},"Swiss Paraplegic Research, Nottwil","NETWORK",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":51,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":55,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":77},"100586228","clinical-efficacy-of-the-erchonia-evrl-for-providing-temporary-relief-of-idiopathic-peripheral-neuropathy-foot-pain-100586228","NCT06912646","Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain","An Evaluation of the Effect of the Erchonia® EVRL™ for Prescription Home Use Application in Providing Temporary Relief From Idiopathic Peripheral Neuropathy Foot Pain","Inclusion Criteria:\n\n* Previously diagnosed with idiopathic peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months.\n* Over the age of 22 years of age\n* Able to read and write English\n* Constant feet pain on-going over at least the past 3 months\n* Subjects using analgesics (pain medication) must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14 days prior to study enrollment; and be willing and able to not have planned upward dose titration of analgesics during the study period. Decreasing frequency of analgesic use during the study is permitted. Cannabis prescribed for medicinal purposes qualifies as an analgesic in this context\n* Willing and able to refrain from engaging in any non-study therapies for the management of foot pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy, hot or cold packs, and alternative therapies such as chiropractic care and acupuncture\n* Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6 hours before a scheduled VAS foot pain rating is to be recorded\n* Subject's degree of foot pain on the 0-100 VAS, with \"0\" being no pain and \"100\" being worst pain imaginable, is 50 or greater\n\nExclusion Criteria:\n\n* Diabetic, referred to as having hemoglobin A1c (HbA1C) of 6.5% or higher\n* Previously diagnosed with any definitive (i.e. not idiopathic) cause of peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months, such as diabetes, injury, infection, toxins and poisons, alcoholism, medications such as chemotherapy, autoimmune disorders, etc..\n* Pregnant or possibly pregnant, breastfeeding, or planning pregnancy during the intended course of study participation\n* Open wounds (sores, cuts, ulcers, etc.) on or around the treatment area on the feet\n* Cancerous growths or lesions on or around the treatment area on the feet\n* Difficulty with hand dexterity sufficient to negatively impact the ability to administer treatments with the laser such as from severe arthritis in the hands, Multiple Sclerosis, Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.","22 Years",{"count":112,"type":20},32,[57],"The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy by a suitably qualified and licensed health professional.",[116,24],"Neuropathy","2025-09-05",{"date":119,"type":35},"2025-09-08",{"date":121,"type":35},"2025-05-01",{"date":123,"type":20},"2027-06-16",{"name":125,"class":126},"Erchonia Corporation","INDUSTRY",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":16,"sex":51,"minAge":52,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":55,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":43},"100514612","short-duration-electrical-stimulation-to-improve-outcomes-after-cubital-tunnel-release-select-trial-100514612","NCT05980767","Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial","SELECT","Inclusion Criteria:\n\n* Ulnar neuropathy at the elbow\n\nExclusion Criteria:\n\n* Peripheral neuropathy outside of nerve of interest\n* Patients with any active implanted device","80 Years",{"count":136,"type":20},26,[57],"A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.",[24],"2025-08-05",{"date":142,"type":35},"2025-08-08",{"date":144,"type":35},"2023-11-01",{"date":146,"type":20},"2025-12",{"name":148,"class":126},"Epineuron Technologies Inc.",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":55,"phases":158,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":77},"100487212","phase-3-the-possible-protective-role-of-ketotifen-against-oxaliplatin-induced-peripheral-neuropathy-100487212","NCT05624138","The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer","Inclusion Criteria:\n\n* Patients with histologically confirmed diagnosis of Stage III colorectal cancer.\n* Patients who will be scheduled to receive modified FOLFOX-6.\n* Patients with no contraindication to chemotherapy.\n* Males and females aged ≥ 18 years old.\n* Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109\u002FL, platelet count ≥ 100 × 109\u002FL and hemoglobin level ≥ 10 g\u002Fdl).\n* Patients with adequate renal function (serum creatinine \\\u003C 1.5 mg\u002Fdl or creatinine clearance (ClCr) ˃ 45 mL\u002Fmin).\n* Patients with adequate liver function (serum bilirubin \\\u003C 1.5 mg\u002Fdl).\n* Patients with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG) score.\n\nExclusion Criteria:\n\n* Children \\\u003C 18 years old.\n* Prior exposure to neurotoxic chemotherapy (Oxaliplatin, cisplatin, vincristine, paclitaxel, or docetaxel, INH) for at least 6 months prior the study treatment.\n* Evidence of pre-existing peripheral neuropathy resulting from another reason (diabetes, brain tumor, brain trauma).\n* Patients with diabetes and other conditions that predispose to neuropathy as hypothyroidism, autoimmune diseases, hepatitis C.\n* History of known allergy to oxaliplatin or other platinum agents.\n* Patients with other inflammatory or stressful conditions.\n* Patients with glaucoma, cataract, other chronic eye disease, seizure, diabetes, heart diseases, low blood pressure, dizziness, vertigo, ménière's disease and CNS disorders.\n* Concomitant use of multivitamins (vitamins E, C, A), tricyclic antidepressants, other neuro-protective medications (gabapentin, lamotrigine, carbamazepine and phenytoin, etc…).\n* Patients on amifampridine, bupropion and donepezil.\n* Concurrent active cancer originating from a primary site other than colon or rectum.\n* Pregnant and breastfeeding women.",{"count":157,"type":20},64,[159],"PHASE3","The aim of current study is to evaluate the possible protective role of Ketotifen against oxaliplatin-induced peripheral sensory neuropathy in patient with stage III colorectal cancer.\n\nThis study will be a randomized placebo controlled parallel study.64 patients with colorectal cancer will be randomized to 2 groups:\n\nGroup I (control group; n=32) which will receive 12 cycles of modified FOLFOX-6 regimen plus placebo tablets twice daily.\n\nGroup II (ketotifen group; n=32) which will receive modified FOLFOX-6 regimen in addition to ketotifen 2 mg daily\n\nBlood sample collection and biochemical assessment:\n\n* Serum IL-6 as a marker of inflammation.\n* Serum superoxide dismutase (SOD) as a biomarker of oxidative stress.\n* Serum neurotensin as a biomarker for neuropathy.\n\nAssessment of oxaliplatin induced peripheral sensory neuropathy will be done through:\n\n* The implication of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 5, 2017) for grading of neuropathy at baseline and by the end of every two oxaliplatin cycles.\n* The use of Neurotoxicity- 12 item questionnaire score (Ntx-12) from the validated Functional Assessment of Cancer Therapy\u002FGynecologic Oncology Group \"FACT\u002FGOG-Ntx-12\" at baseline and by the end of every two oxaliplatin cycles.\n* The assessment of the severity of neuropathic pain through brief pain inventory short form \"BPI-SF\" worst item. Severity of neuropathic pain will be assessed at baseline and by the end of every two oxaliplatin cycles.",[24],"2025-05-09",{"date":164,"type":35},"2025-05-11",{"date":166,"type":35},"2022-11-09",{"date":168,"type":20},"2025-06",{"name":170,"class":42},"Tanta University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":55,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":77},"100552317","neuroprosthetic-device-for-improving-issues-caused-by-diabetic-neuropathy-with-specifically-designed-neural-stimulation-100552317","NCT06471517","Neuroprosthetic Device for Improving Issues Caused by Diabetic Neuropathy With Specifically Designed Neural Stimulation","DiabeticStim","Inclusion Criteria:\n\n* Diagnosed polyneuropathy\n* Ability to stand and walk unassisted.\n* Sensory loss in the feet\n\nExclusion Criteria:\n\n* Open ulcers on the feet\n* Pregnancy\n* History of or current psychological diseases that include schizophrenia and major depression\n* Hypersensitivity to electrical stimulation",{"count":179,"type":20},20,[57],"Neuropathy refers to a condition that results from damage to the peripheral nerves.The most common cause of it is diabetes mellitus, metabolic disorder that affects more than 422 million individuals worldwide, putting a huge strain on the healthcare system and up to 50% of these individuals will develop neuropathy. Peripheral neuropathy is characterized by sensory nerve abnormalities such as an impaired sense of touch. Sensory loss in feet can lead to functional deficits during gait, low balance, and increased risk of falls and is considered the strongest risk factor for diabetic foot ulceration. Moreover, these patients usually also suffer from neuropathic pain, which is believed to be associated with aberrant sensory input.\n\nWith this in mind, the study aims to understand the effects of restoring sensation lost to neuropathy using transcutaneous electrical stimulation. Additionally, the investigators aim to understand if electrical stimulation of the damaged nerves can reduce health consequences such as chronic pain.\n\nTo achieve this, the investigators have developed a wearable sensory restoration system that can restore lost sensation with non-invasive, precisely controlled electrical stimulation through electrodes integrated into the sock garment. A system is composed of a system controller that communicates via Bluetooth with force-sensitive insoles placed in the shoes and neurostimulators directly connected to electrode array socks. Based on the insole recordings the stimulation parameters are defined in real-time, making it a closed-loop system for restoring somatotopic sensory feedback.",[24,183,184],"Neuropathy, Diabetic","Neuropathy, Painful","2024-06-18",{"date":187,"type":35},"2024-06-24",{"date":189,"type":35},"2024-06-13",{"date":191,"type":20},"2025-07-31",{"name":193,"class":42},"Institute Mihajlo Pupin",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":55,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":77},"100548588","efficacy-and-safety-of-hiloterm-device-for-the-prevention-of-peripheral-neuropathy-100548588","NCT06422949","Efficacy and Safety of HILOTERM® Device for the Prevention of Peripheral Neuropathy","A Study on the Efficacy and Safety of HILOTERM® Device for the Prevention of Chemotherapy-induced Peripheral Neuropathy in Early Breast Cancer Patients","Inclusion Criteria:\n\n* Women \\> 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Radically operated infiltrating breast cancer, pT1-T3, pN0-2, M0\n* Candidate to adjuvant chemotherapy that includes weekly paclitaxel 80 mg\u002Fm2 intravenous for 12 weeks \\[either following anthracyclines and\u002For in association with trastuzumab\\]\n* Negative pregnancy test at baseline (in fertile women)\n* Willing and able to sign informed consent for protocol treatment\n\nExclusion Criteria:\n\n* Evidence of metastatic disease (M1)\n* pT4 and\u002For pN3\n* Previous or concomitant malignancy of any other type\n* Previous treatment with chemotherapy, hormonal therapy or an investigational drug for any type of malignancy\n* Plans to use a chemotherapy regimen other than those specified in the inclusion criteria\n* Any serious concurrent infection or any clinically significant medical illness (in particular clinically significant liver disease, clinically significant renal dysfunction, clinically significant cardiovascular disease, uncontrolled infections) which would jeopardize the ability of the patient to complete the planned therapy and follow-up\n* Pre-existing motor or sensory neuropathy of any grade, for any reason\n* Participation in any other clinical investigation or exposure to other investigational agents, drugs, device or procedure that may cause PN\n* History of Raynaud phenomenon, either primary or secondary to autoimmune or connective tissue diseases such as systemic lupus erythematous, scleroderma, Buerger disease, Sjögren syndrome, rheumatoid arthritis, occlusive vascular disease, such as atherosclerosis, polymyositis, cold agglutinin disease or cryoglobulinemia, thyroid disorders, pulmonary hypertension\n* Cold urticaria \u002F cold contact urticaria\n* Severe arterial disease\n* Trophic tissue lesions\n* Diabetes mellitus\n* Alcohol abuse\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to the components of Hilotherm Chemo care device\n* Simultaneous use of Dignicap system to prevent hair loss from chemotherapy",{"count":202,"type":20},120,[57],"Taxol is a very effective drug in breast cancer, but it can cause peripheral neuropathy (PN). This toxicity is often dose-limiting. Symptoms of PN usually improve after taxol discontinuation, but \\>80% of affected women experience symptoms 1-3 years after treatment stop. The intensity, the duration and the type of symptoms related to PN are very different and they can strongly interfere with patients' quality of life.\n\nThe application of cold to the hands and feet seems to be able to reduce the incidence of PN. Hilotherm® is a machine that allows to cool hands and feet. The aim of this study is to verify whether the use of Hilotherm® is able to reduce the incidence of moderate and severe PN and to evaluate the tolerability of Hilotherm® and its impact on quality of life.",[206,24],"Breast Cancer",[208,209,210],"Early stage breast cancer","Paclitaxel","Chemotherapy-induced peripheral neuropathy","NOT_YET_RECRUITING","2024-05-30",{"date":214,"type":35},"2024-05-31",{"date":216,"type":20},"2024-06-15",{"date":218,"type":20},"2027-08-15",{"name":220,"class":42},"European Institute of Oncology",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":55,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":77},"100416213","peripheral-nerve-block-in-patients-with-painful-diabetic-polyneuropathy-100416213","NCT04699734","Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy","Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy: How Important is the Peripheral Signaling?","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Probably diabetic neuropathy confirmed using the Toronto criteria in a \"conservative manner\", i.e. three out of three symptoms\u002Fsigns of neuropathy must be present (sensory neuropathy symptoms, distal reduced sensibility, reduced ankle reflexes) 7.\n* Definite or probable neuropathic pain for minimum the last 6 months\n* Mean pain intensity at \\> 4 NRS the last week17.\n\nSince we expect a large effect of the block it is not necessary to discontinue pain medication.\n\nExclusion Criteria:\n\n* Other causes of pain in the same area or other pain that cannot be distinguished from the neuropathic pain.\n* Unable to understand and speak Danish.\n* Non-cooperative.\n* Warfarin or other medication that contraindicate regional anesthesia.\n* Infection in the injection area.\n* Allergy to lidocaine.\n* Pregnancy or lactating (fertile women must to show negative pregnancy test or use anticonception).\n* Severe psychiatric disease e.g. severe depression during the last 6 months.\n* Alcohol or drug abuse.",{"count":229,"type":20},16,[57],"The purpose of the present study is to evaluate the role of peripheral afferent input for spontaneous pain in painful diabetic polyneuropathy",[233,234,24],"Painful Diabetic Neuropathy","Neuropathic Pain","2021-01-06",{"date":237,"type":35},"2021-01-07",{"date":239,"type":35},"2020-09-08",{"date":241,"type":20},"2026-12-31",{"name":243,"class":42},"University of Aarhus",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":16,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":55,"phases":253,"briefSummary":255,"conditions":256,"keywords":273,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100354774","phase-1-safety-and-clinical-outcomes-with-amniotic-and-umbilical-cord-tissue-therapy-for-numerous-medical-conditions-100354774","NCT03899298","Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions","Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions","Inclusion Criteria:\n\n1. Age 18 and over.\n2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.\n3. Competent to understand the study protocol and provide voluntary informed consent.\n4. Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back\u002FNeck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.\n\nExclusion Criteria:\n\n1. Active Cancer\n2. Pregnancy, Lactating\n3. Severe Clotting disorder\n4. Myocardial Infarction less than six months ago.",{"count":252,"type":20},5000,[254],"PHASE1","To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.",[257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,24,272],"Orthopedic Disorder","Neurologic Disorder","Urologic Diseases","Erectile Dysfunction","Autoimmune Diseases","Renal Failure","Renal Insufficiency","Kidney Diseases","Cardiac Event","Cardiomyopathies","CHF","Pulmonary Disease","COPD","Alzheimer Disease","Stroke","Arthritis",[274,275,276,277,278,279,280,281],"stem cell therapy","umbilical stem cells","amniotic stem cells","stem cells","regenerative medicine","r3 stem cell","perinatal tissue","placenta stem cell","2019-08-20",{"date":284,"type":35},"2019-08-22",{"date":286,"type":20},"2019-09-01",{"date":288,"type":20},"2029-03-20",{"name":290,"class":126},"R3 Stem Cell"]